

14 March 2019

ImmuPharma PLC
("ImmuPharma" or the "Company")

CORPORATE UPDATE

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update on ongoing activities.

Key highlights:

- Lupuzor™
 - Lupuzor™ 'Managed Access Program'
 - Phase III 'open label extension'
- Nucant (cancer) program: Clinical development collaboration with Incanthera Limited
- Urelix technology

Lupuzor™

Lupuzor™ is the Company's late stage asset for Lupus, a potential life threatening auto-immune disease. Following the conclusion of the pivotal Phase III trial earlier in 2018, ImmuPharma continues to look at opportunities which over the longer term have the potential of bringing Lupuzor™ to market. As part of this strategy, the Company continues to engage with potential corporate partners as well as commencing a Managed Access Program for Lupuzor™.

Lupuzor™ Managed Access Program

ImmuPharma, together with its partner, is in the final preparations for its Managed Access Program ('MAP') being open to eligible patients in Europe. Further updates will be provided to the market in due course.

Lupuzor™ Extension Study

The Lupuzor™ open label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in Q2 2019.

Nucant Cancer Programme – Clinical Development Collaboration

As announced on 31 December 2018, the exclusivity period was extended to 31 March 2019. Discussions continue on this collaboration and an update will be provided in due course.

Ureka

ImmuPharma's subsidiary, Ureka Sarl ("Ureka") based in Bordeaux, is focusing on transforming peptides into efficient drugs for treatments in a number of therapeutic areas including Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis). Recently, a fundamental research paper on Ureka's proprietary technology 'Urelix™' was published in the peer reviewed research journal 'Nature Communications'.

ImmuPharma continues to look at all options regarding progression of Ureka's assets. This process is ongoing and further updates will be announced as appropriate.

Commenting on the announcement, Tim McCarthy, ImmuPharma's Chairman said: *"We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor™, whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects."*

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact:

| | |
|--|-----------------------|
| ImmuPharma plc (www.immupharma.com) | + 44 (0) 207 152 4080 |
| Tim McCarthy, Chairman | |
| Lisa Baderoon, Head of Investor Relations | + 44 (0) 7721 413496 |
| SPARK Advisory Partners Limited (NOMAD) | +44 (0) 203 368 8974 |
| Neil Baldwin | |
| Vassil Kirtchev | |
| Stanford Capital Partners (Joint Broker) | +44 (0) 203 815 8880 |
| Patrick Claridge, John Howes | |
| SI Capital (Joint Broker) | +44 (0) 1483 413500 |
| Nick Emerson | |